{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:51:07Z","timestamp":1767174667980,"version":"build-2238731810"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2159-7","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T00:35:10Z","timestamp":1456360510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-0149","authenticated-orcid":false,"given":"Yusuke","family":"Okuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuru","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunekazu","family":"Hishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,25]]},"reference":[{"issue":"4","key":"2159_CR1","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/annonc\/mdu033","volume":"25","author":"PG Casali","year":"2014","unstructured":"Casali PG. Rare cancers: work in progress in Europe. Ann Oncol. 2014;25(4):914.","journal-title":"Ann Oncol"},{"issue":"17","key":"2159_CR2","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","volume":"47","author":"G Gatta","year":"2011","unstructured":"Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47(17):2493\u2013511.","journal-title":"Eur J Cancer"},{"key":"2159_CR3","unstructured":"RARE CANCERS EUROPE. http:\/\/www.rarecancerseurope.org\/ . Accessed 14 Feb 2016."},{"issue":"2","key":"2159_CR4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/annonc\/mdu459","volume":"26","author":"PG Casali","year":"2015","unstructured":"Casali PG, Bruzzi P, Bogaerts J, Blay JY, Rare Cancers Europe Consensus P. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Ann Oncol. 2015;26(2):300\u20136.","journal-title":"Ann Oncol"},{"issue":"1","key":"2159_CR5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","volume":"44","author":"WK Jong de","year":"2008","unstructured":"de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer. 2008;44(1):123\u201330.","journal-title":"Eur J Cancer"},{"issue":"10 Suppl 4","key":"2159_CR6","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","volume":"5","author":"EA Engels","year":"2010","unstructured":"Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010;5(10 Suppl 4):S260\u20135.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2159_CR7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/cncr.10226","volume":"94","author":"M Okumura","year":"2002","unstructured":"Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer. 2002;94(3):624\u201332.","journal-title":"Cancer"},{"issue":"4","key":"2159_CR8","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.athoracsur.2003.07.042","volume":"77","author":"K Kondo","year":"2004","unstructured":"Kondo K, Yoshizawa K, Tsuyuguchi M, Kimura S, Sumitomo M, Morita J, et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg. 2004;77(4):1183\u20138.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"2159_CR9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ejcts.2004.04.041","volume":"26","author":"F Rea","year":"2004","unstructured":"Rea F, Marulli G, Girardi R, Bortolotti L, Favaretto A, Galligioni A, et al. Long-term survival and prognostic factors in thymic epithelial tumours. Eur J Cardiothorac Surg. 2004;26(2):412\u20138.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"5","key":"2159_CR10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/era.12.29","volume":"12","author":"N Girard","year":"2012","unstructured":"Girard N. Chemotherapy and targeted agents for thymic malignancies. Expert Rev Anticancer Ther. 2012;12(5):685\u201395.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"2159_CR11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","volume":"141","author":"Y Okuma","year":"2015","unstructured":"Okuma Y, Saito M, Hosomi Y, Sakuyama T, Okamura T. Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol. 2015;141(2):323\u201331.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"2159_CR12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.6004\/jnccn.2013.0072","volume":"11","author":"DS Ettinger","year":"2013","unstructured":"Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, et al. Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013;11(5):562\u201376.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2159_CR13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","volume":"16","author":"A Thomas","year":"2015","unstructured":"Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16(2):177\u201386.","journal-title":"Lancet Oncol"},{"key":"2159_CR14","doi-asserted-by":"crossref","unstructured":"Zucali PA, De Pas TM, Palmieri G, Favaretto AG, Chella A, Tiseo M, et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol. 2014;32(suppl):abstr 7527.","DOI":"10.1200\/jco.2014.32.15_suppl.7527"},{"issue":"3","key":"2159_CR15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cllc.2014.10.006","volume":"16","author":"Y Okuma","year":"2015","unstructured":"Okuma Y, Hosomi Y, Takahashi S, Maeda Y, Okamura T, Hishima T. Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinoma. Clin Lung Cancer. 2015;16(3):221\u20137.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"2159_CR16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.lungcan.2010.09.004","volume":"70","author":"Y Okuma","year":"2010","unstructured":"Okuma Y, Shimokawa T, Takagi Y, Hosomi Y, Iguchi M, Okamura T, et al. S-1 is an active anticancer agent for advanced thymic carcinoma. Lung Cancer. 2010;70(3):357\u201363.","journal-title":"Lung Cancer"},{"issue":"2","key":"2159_CR17","first-page":"73","volume":"473","author":"PV Danenberg","year":"1977","unstructured":"Danenberg PV. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta. 1977;473(2):73\u201392.","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"2159_CR18","first-page":"2672","volume":"5","author":"RB Diasio","year":"1999","unstructured":"Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res. 1999;5(10):2672\u20133.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2159_CR19","first-page":"20","volume":"46","author":"GJ Peters","year":"1986","unstructured":"Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5\u2032-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 1986;46(1):20\u20138.","journal-title":"Cancer Res"},{"issue":"10","key":"2159_CR20","first-page":"2371","volume":"4","author":"R Metzger","year":"1998","unstructured":"Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res. 1998;4(10):2371\u20136.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2159_CR21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.lungcan.2012.12.003","volume":"79","author":"V Monica","year":"2013","unstructured":"Monica V, Familiari U, Chiusa L, Rossi G, Novero D, Busso S, et al. Messenger RNA and protein expression of thymidylate synthase and DNA repair genes in thymic tumors. Lung Cancer. 2013;79(3):228\u201335.","journal-title":"Lung Cancer"},{"issue":"7 Suppl 3","key":"2159_CR22","first-page":"S1689","volume":"6","author":"ITMIG","year":"2011","unstructured":"ITMIG. Definitions and Policies. J Thorac Oncol. 2011;6(7 Suppl 3):S1689\u2013S755.","journal-title":"J Thorac Oncol"},{"issue":"1-2","key":"2159_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jim.2003.08.002","volume":"283","author":"A Bonanomi","year":"2003","unstructured":"Bonanomi A, Kojic D, Giger B, Rickenbach Z, Jean-Richard-Dit-Bressel L, Berger C, et al. Quantitative cytokine gene expression in human tonsils at excision and during histoculture assessed by standardized and calibrated real-time PCR and novel data processing. J Immunol Methods. 2003;283(1-2):27\u201343.","journal-title":"J Immunol Methods"},{"key":"2159_CR24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1471-2199-8-114","volume":"8","author":"S Perez","year":"2007","unstructured":"Perez S, Royo LJ, Astudillo A, Escudero D, Alvarez F, Rodriguez A, et al. Identifying the most suitable endogenous control for determining gene expression in hearts from organ donors. BMC Mol Biol. 2007;8:114.","journal-title":"BMC Mol Biol"},{"issue":"3","key":"2159_CR25","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","volume":"14","author":"G Giaccone","year":"1996","unstructured":"Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1996;14(3):814\u201320.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2159_CR26","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1200\/JCO.2003.09.130","volume":"21","author":"GA Masters","year":"2003","unstructured":"Masters GA, Declerck L, Blanke C, Sandler A, DeVore R, Miller K, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol. 2003;21(8):1550\u20135.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2159_CR27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jjco\/hyf059","volume":"32","author":"S Umemura","year":"2002","unstructured":"Umemura S, Segawa Y, Fujiwara K, Takata I, Seki N, Tokuda Y, et al. A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy. Jpn J Clin Oncol. 2002;32(7):262\u20135.","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"2159_CR28","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","volume":"17","author":"MS Highley","year":"1999","unstructured":"Highley MS, Underhill CR, Parnis FX, Karapetis C, Rankin E, Dussek J, et al. Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol. 1999;17(9):2737\u201344.","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2159_CR29","doi-asserted-by":"crossref","first-page":"abstr 7079","DOI":"10.1200\/jco.2006.24.18_suppl.7079","volume":"18","author":"PJ Loehrer","year":"2006","unstructured":"Loehrer PJ, Yiannoutsos CT, Dropcho S, Burns M, Helft P, Chiorean EG, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol. 2006;18(suppl):abstr 7079.","journal-title":"J Clin Oncol"},{"issue":"2B","key":"2159_CR30","first-page":"1331","volume":"17","author":"CH Hsu","year":"1997","unstructured":"Hsu CH, Yeh KH, Cheng AL. Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin. Anticancer Res. 1997;17(2B):1331\u20134.","journal-title":"Anticancer Res"},{"issue":"6","key":"2159_CR31","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","volume":"15","author":"K Oberg","year":"2004","unstructured":"Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966\u201373.","journal-title":"Ann Oncol"},{"issue":"7 Suppl 3","key":"2159_CR32","doi-asserted-by":"crossref","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","volume":"6","author":"N Girard","year":"2011","unstructured":"Girard N, Lal R, Wakelee H, Riely GJ, Loehrer PJ. Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol. 2011;6(7 Suppl 3):S1749\u201355.","journal-title":"J Thorac Oncol"},{"issue":"suppl","key":"2159_CR33","doi-asserted-by":"crossref","first-page":"abstr 7580","DOI":"10.1200\/jco.2015.33.15_suppl.7580","volume":"33","author":"H Wakelee","year":"2015","unstructured":"Wakelee H, Padda S, Burns M, Spittler A, Riess J, San Pedro-Salcedo M, et al. Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM). J Clin Oncol. 2015;33(suppl):abstr 7580.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2159_CR34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/jjco\/hyv046","volume":"45","author":"N Watanabe","year":"2015","unstructured":"Watanabe N, Umemura S, Niho S, Kirita K, Matsumoto S, Yoh K, et al. Docetaxel for platinum-refractory advanced thymic carcinoma. Jpn J Clin Oncol. 2015;45(7):665\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"2159_CR35","first-page":"299","volume":"31","author":"T Koizumi","year":"2011","unstructured":"Koizumi T, Agatsuma T, Komatsu Y, Kubo K. Successful S-1 monotherapy for chemorefractory thymic carcinoma. Anticancer Res. 2011;31(1):299\u2013301.","journal-title":"Anticancer Res"},{"issue":"9","key":"2159_CR36","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/JTO.0b013e318183af9c","volume":"3","author":"A Ono","year":"2008","unstructured":"Ono A, Naito T, Yamamoto N. S-1 treatment for chemorefractory thymic carcinoma. J Thorac Oncol. 2008;3(9):1076.","journal-title":"J Thorac Oncol"},{"key":"2159_CR37","volume-title":"World Health Organization classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Chapter 3","author":"W Travis","year":"2004","unstructured":"Travis W, Brambilla W, M\u00fcller-Hermelink H, Harris C. World Health Organization classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Chapter 3. Lyon: IARC press; 2004."},{"issue":"16","key":"2159_CR38","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.ejca.2015.06.121","volume":"51","author":"T Stachowicz-Stencel","year":"2015","unstructured":"Stachowicz-Stencel T, Orbach D, Brecht I, Schneider D, Bien E, Synakiewicz A, et al. Thymoma and thymic carcinoma in children and adolescents: A report from the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Eur J Cancer. 2015;51(16):2444\u201352.","journal-title":"Eur J Cancer"},{"issue":"25","key":"2159_CR39","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","volume":"350","author":"P Strobel","year":"2004","unstructured":"Strobel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med. 2004;350(25):2625\u20136.","journal-title":"N Engl J Med"},{"issue":"2","key":"2159_CR40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","volume":"26","author":"XF Li","year":"2009","unstructured":"Li XF, Chen Q, Huang WX, Ye YB. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol. 2009;26(2):157\u201360.","journal-title":"Med Oncol"},{"issue":"2","key":"2159_CR41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","volume":"103","author":"P Strobel","year":"2010","unstructured":"Strobel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer. 2010;103(2):196\u2013200.","journal-title":"Br J Cancer"},{"issue":"9","key":"2159_CR42","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/annonc\/mdr626","volume":"23","author":"L Schirosi","year":"2012","unstructured":"Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S, et al. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol. 2012;23(9):2409\u201314.","journal-title":"Ann Oncol"},{"issue":"3","key":"2159_CR43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.lungcan.2011.04.001","volume":"74","author":"K Kaira","year":"2011","unstructured":"Kaira K, Serizawa M, Koh Y, Miura S, Kaira R, Abe M, et al. Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. Lung Cancer. 2011;74(3):419\u201325.","journal-title":"Lung Cancer"},{"issue":"2","key":"2159_CR44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","volume":"88","author":"Y Katsuya","year":"2015","unstructured":"Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer. 2015;88(2):154\u20139.","journal-title":"Lung Cancer"},{"issue":"3","key":"2159_CR45","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","volume":"10","author":"SK Padda","year":"2015","unstructured":"Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015;10(3):500\u20138.","journal-title":"J Thorac Oncol"},{"key":"2159_CR46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2014.11.006","volume":"87","author":"Y Liang","year":"2015","unstructured":"Liang Y, Padda SK, Riess JW, West RB, Neal JW, Wakelee HA. Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer. 2015;87:34\u20138.","journal-title":"Lung Cancer"},{"key":"2159_CR47","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2217\/fon.14.144","volume":"10","author":"G Palmieri","year":"2014","unstructured":"Palmieri G, Buonerba C, Ottaviano M, Federico P, Calabrese F, Von Arx C, et al. Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. Future Oncol. 2014;10:2141\u20137.","journal-title":"Future Oncol"},{"key":"2159_CR48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","volume":"15","author":"A Rajan","year":"2014","unstructured":"Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15:191\u2013200.","journal-title":"Lancet Oncol"},{"key":"2159_CR49","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","volume":"29","author":"G Giaccone","year":"2011","unstructured":"Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011;29:2052\u20139.","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2159_CR50","doi-asserted-by":"crossref","first-page":"abstr 7526","DOI":"10.1200\/jco.2014.32.15_suppl.7526","volume":"32","author":"B Besse","year":"2014","unstructured":"Besse B, Garassino MC, Rajan A, Novello S, Mazieres J, Weiss GJ, et al. A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). J Clin Oncol. 2014;32(suppl):abstr 7526.","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2159_CR51","doi-asserted-by":"crossref","first-page":"abstr 19087","DOI":"10.1200\/jco.2008.26.15_suppl.19087","volume":"26","author":"PM Bedano","year":"2008","unstructured":"Bedano PM, Perkins S, Burns M, Kessler K, Nelson R, Schneider BP, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol. 2008;26(suppl):abstr 19087.","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2159_CR52","doi-asserted-by":"crossref","first-page":"abstr 7068","DOI":"10.1200\/jco.2005.23.16_suppl.7068","volume":"23","author":"A Kurup","year":"2005","unstructured":"Kurup A, Burns M, Dropcho S. Phase II study of Gefitinib treatment in advanced thymic malignancies. J Clin Oncol. 2005;23(suppl):abstr 7068.","journal-title":"J Clin Oncol"},{"key":"2159_CR53","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","volume":"4","author":"G Giaccone","year":"2009","unstructured":"Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol. 2009;4:1270\u20133.","journal-title":"J Thorac Oncol"},{"key":"2159_CR54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","volume":"22","author":"PJ Loehrer Sr","year":"2004","unstructured":"Loehrer Sr PJ, Wang W, Johnson DH, Aisner SC, Ettinger DS. Eastern Cooperative Oncology Group Phase IIT. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004;22:293\u20139.","journal-title":"J Clin Oncol"},{"key":"2159_CR55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2015.04.008","volume":"89","author":"MA Gubens","year":"2015","unstructured":"Gubens MA, Burns M, Perkins SM, Pedro-Salcedo MS, Althouse SK, Loehrer PJ, et al. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. Lung Cancer. 2015;89:57\u201360.","journal-title":"Lung Cancer"}],"updated-by":[{"DOI":"10.1186\/s12885-016-2309-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T00:00:00Z","timestamp":1460678400000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2159-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T22:10:17Z","timestamp":1600207817000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2407\/16\/156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,25]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2159"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2159-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,25]]},"article-number":"156"}}